ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia
Open Access
- 15 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (14) , 4357-4363
- https://doi.org/10.1158/1078-0432.ccr-05-2587
Abstract
Background: A major issue in the treatment of acute myeloid leukemia (AML) is resistance to chemotherapeutic drugs. Multidrug resistance can be caused by ATP-binding cassette (ABC) transporters that function as drug efflux pumps. The majority of these proteins have not yet been examined in malignant diseases.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Expression of Multidrug Resistance–Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic LeukemiaClinical Cancer Research, 2005
- Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter GenesCancer Research, 2004
- The use of housekeeping genes for real-time PCR-based quantification of fusion gene transcripts in acute myeloid leukemiaLeukemia, 2004
- The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotypeBlood, 2003
- Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AMLLeukemia, 2003
- BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemiaLeukemia, 2002
- Mammalian ABC Transporters in Health and DiseaseAnnual Review of Biochemistry, 2002
- The Role of Drug Efflux Pumps in Acute Myeloid LeukemiaLeukemia & Lymphoma, 2002
- Verbesserte Ergebnisse in der Therapie der akuten myeloischen Leukämie - Ergebnisse der Therapiestudie AML-BFM-93 in den neuen Bundesländern im Vergleich mit den Vorgängerstudien AML-I/82 und AML-II/87 der DDRKlinische Padiatrie, 2001
- Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93Leukemia, 2001